285 related articles for article (PubMed ID: 10492357)
41. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
Cremerius U; Fabry U; Kröll U; Zimny M; Neuerburg J; Osieka R; Büll U
Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778
[TBL] [Abstract][Full Text] [Related]
42. PET/MRI for the evaluation of patients with lymphoma: initial observations.
Heacock L; Weissbrot J; Raad R; Campbell N; Friedman KP; Ponzo F; Chandarana H
AJR Am J Roentgenol; 2015 Apr; 204(4):842-8. PubMed ID: 25794075
[TBL] [Abstract][Full Text] [Related]
43. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma.
Newman EN; Jones RL; Hawkins DS
Pediatr Blood Cancer; 2013 Jul; 60(7):1113-7. PubMed ID: 23192939
[TBL] [Abstract][Full Text] [Related]
44. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma.
Yamamoto F; Tsukamoto E; Nakada K; Takei T; Zhao S; Asaka M; Tamaki N
Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753
[TBL] [Abstract][Full Text] [Related]
45. Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm.
Pezeshk P; Sadow CA; Winalski CS; Lang PK; Ready JE; Carrino JA
Acad Radiol; 2006 Aug; 13(8):1011-5. PubMed ID: 16843854
[TBL] [Abstract][Full Text] [Related]
46. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
47. [Malignant lymphoma].
Okamoto R
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2532-6. PubMed ID: 20009452
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
[TBL] [Abstract][Full Text] [Related]
49. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET.
Adams HJ; Kwee TC; Vermoolen MA; de Keizer B; de Klerk JM; Adam JA; Fijnheer R; Kersten MJ; Stoker J; Nievelstein RA
Eur Radiol; 2013 Aug; 23(8):2271-8. PubMed ID: 23591618
[TBL] [Abstract][Full Text] [Related]
50. Staging non-small cell lung cancer with whole-body PET.
Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
[TBL] [Abstract][Full Text] [Related]
51. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
52. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).
Jerusalem G; Beguin Y; Najjar F; Hustinx R; Fassotte MF; Rigo P; Fillet G
Ann Oncol; 2001 Jun; 12(6):825-30. PubMed ID: 11484959
[TBL] [Abstract][Full Text] [Related]
53. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
Mruck S; Baum RP; Rinne D; Hör G
Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
[TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease.
Wiedmann E; Baican B; Hertel A; Baum RP; Chow KU; Knupp B; Adams S; Hör G; Hoelzer D; Mitrou PS
Leuk Lymphoma; 1999 Aug; 34(5-6):545-51. PubMed ID: 10492078
[TBL] [Abstract][Full Text] [Related]
56. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.
Bury T; Barreto A; Daenen F; Barthelemy N; Ghaye B; Rigo P
Eur J Nucl Med; 1998 Sep; 25(9):1244-7. PubMed ID: 9724372
[TBL] [Abstract][Full Text] [Related]
57. [18F-FDG PET/CT in lymphomas: assessment difficulties due to illness characteristics, and comparison with literature data].
Garai I; Borbély K; Barna S; Szûcs B; Hascsi Z; Tóth Z; Illés A
Magy Onkol; 2011 Sep; 55(3):178-86. PubMed ID: 21918743
[TBL] [Abstract][Full Text] [Related]
58. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study.
Bar-Shalom R; Yefremov N; Haim N; Dann EJ; Epelbaum R; Keidar Z; Gaitini D; Frenkel A; Israel O
Radiology; 2003 May; 227(2):353-60. PubMed ID: 12637679
[TBL] [Abstract][Full Text] [Related]
59. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?
Kostakoglu L; Goldsmith SJ
Eur J Nucl Med; 2000 Oct; 27(10):1564-78. PubMed ID: 11083548
[TBL] [Abstract][Full Text] [Related]
60. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
Bar-Shalom R
Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
